Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Mild to Moderate Essential Hypertension

NCT02031861 ↗

Phase 4 Completed 38 enrolled Shanghai Shyndec Pharmaceutical Co., Ltd.

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare nifedipine controlled-release (CR) tablets (Xin Ran) with nifedipine controlled-release tablets (Adalat）in the treatment of mild to moderate essential hypertension.

Timeline

Start: 2014-02
Primary completion: 2014-07
Completion: 2014-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Nifedipine	Other / unclassified	30 mg	Oral

Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Mild to Moderate Essential Hypertension

Summary

Timeline

Drugs

Indications